Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome is applying its distinctive Kinobeads™ technology to the discovery and development of novel, selective, kinase inhibitors targeting key inflammatory mediators in immune receptor signalling and chemotaxis, including PI3Kγ and Zap-70.